JP6549577B2 - 糖尿病管理用ボーラス投与フィードバック - Google Patents
糖尿病管理用ボーラス投与フィードバック Download PDFInfo
- Publication number
- JP6549577B2 JP6549577B2 JP2016534654A JP2016534654A JP6549577B2 JP 6549577 B2 JP6549577 B2 JP 6549577B2 JP 2016534654 A JP2016534654 A JP 2016534654A JP 2016534654 A JP2016534654 A JP 2016534654A JP 6549577 B2 JP6549577 B2 JP 6549577B2
- Authority
- JP
- Japan
- Prior art keywords
- glucose
- bolus
- rate
- trend
- change
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 121
- 239000008103 glucose Substances 0.000 claims description 121
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 64
- 102000004877 Insulin Human genes 0.000 claims description 32
- 108090001061 Insulin Proteins 0.000 claims description 32
- 229940125396 insulin Drugs 0.000 claims description 32
- 230000008859 change Effects 0.000 claims description 23
- 238000005259 measurement Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 11
- 238000004364 calculation method Methods 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 238000007726 management method Methods 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 230000002641 glycemic effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940125697 hormonal agent Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000035860 hypoinsulinemia Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001824 photoionisation detection Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Data Mining & Analysis (AREA)
- Chemical & Material Sciences (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Description
本国際特許出願は、2013年12月5日出願の先行出願された米国特許出願第14/098,353号のパリ条約及びアメリカ合衆国法典第35巻「特許法」第119条に基づく優先権の利益を主張するものであり、この先行出願は、参照により本明細書に組み入れられる。
米国特許第7,060,059号、
米国特許出願第2011/0313680及び同第2011/0257627号、
国際公開第2012/051344号、
Percival et al.,「Closed−Loop Control and Advisory Mode Evaluation of an Artificial Pancreatic β Cell:Use of Proportional−Integral−Derivative Equivalent Model−Based Controllers」Journal of Diabetes Science and Technology,Vol.2,Issue 4,July 2008、
Paola Soru et al..,「MPC Based Artificial Pancreas;Strategies for Individualization and Meal Compensation」Annual Reviews in Control 36,p.118〜128(2012)、
Cobelli et al.,「Artificial Pancreas:Past,Present,Future」Diabetes Vol.60,Nov.2011、
Magni et al.,「Run−to−Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects:In Silico Trial」Journal of Diabetes Science and Technology,Vol.3,Issue 5,September 2009、
Lee et al.,「A Closed−Loop Artificial Pancreas Using Model Predictive Control and a Sliding Meal Size Estimator」Journal of Diabetes Science and Technology,Vol.3,Issue 5,September 2009、
Lee et al.,「A Closed−Loop Artificial Pancreas based on MPC:Human Friendly Identification and Automatic Meal Disturbance Rejection」Proceedings of the 17th World Congress,The International Federation of Automatic Control,Seoul Korea July 6〜11,2008、
Magni et al.,「Model Predictive Control of Type 1 Diabetes:An in Silico Trial」Journal of Diabetes Science and Technology,Vol.1,Issue 6,November 2007、
Wang et al.,「Automatic Bolus and Adaptive Basal Algorithm for the Artificial Pancreatic β−Cell」Diabetes Technology and Therapeutics,Vol.12,No.11,2010、及び、
Percival et al.,「Closed−Loop Control of an Artificial Pancreatic β−Cell Using Multi−Parametric Model Predictive Control」Diabetes Research 2008。
Claims (9)
- 輸液ポンプと、少なくとも1つのグルコースモニターと、マイクロコントローラとを有する糖尿病管理システムを前記マイクロコントローラが操作する方法であって、前記方法は前記マイクロコントローラで実行される以下のステップ:
グルコースを有する流体サンプルが酵素副産物に変換されるグルコース測定を判定するステップと、
前記判定するステップにより行われた前記グルコース測定に基づいてボーラス推奨値を計算するステップと、
前記ボーラス推奨値が前記システムのユーザーにより従われたかどうか評価するステップであって、
前記ボーラス推奨値が前記ユーザーにより従われなかった場合、
前記輸液ポンプにより送達された実際のボーラスを記憶することと、
その後の流体サンプル中のグルコース値を測定することであって、経時的なグルコース値の変化率が所定の高い変化率の傾向閾値を上回る場合、推奨ボーラス及びポンプにより送達された実際のボーラスとともにグルコース値の高い変化率の傾向を報知し、経時的なグルコース値の変化率が所定の低い変化率の傾向閾値を下回る場合、推奨ボーラス及びポンプにより送達された実際のボーラスとともにグルコース値の低い変化率の傾向を報知する、ステップと、
を含む、方法。 - 前記コントローラにおいて前記測定するステップによって行われた前記グルコース測定を記憶するステップを更に含む、請求項1に記載の方法。
- 前記ユーザーが前記コントローラに入力した生活イベントに関する情報に基づいて、別のボーラス計算の必要性を判定するステップを更に含む、請求項1に記載の方法。
- 前記グルコースモニターは連続グルコースモニターを含み、前記マイクロコントローラは閉ループコントローラを含む、請求項1に記載の方法。
- 前記グルコース値の高い変化率の傾向を報知することは、グルコース測定の測定結果の傾向が、前記推奨ボーラス及び送達される前記実際のボーラスとともにボーラス送達後に増加しているというメッセージを表示することを含む、請求項4に記載の方法。
- 前記グルコース値の低い変化率の傾向を報知することは、グルコース測定の測定結果の傾向が、前記推奨ボーラス及び送達される前記実際のボーラスとともにボーラス送達後に減少しているというテキストメッセージを表示することを含む、請求項4に記載の方法。
- 前記低い変化率の傾向閾値は、30分毎に20mg/dLのグルコース濃度の低下率であり、前記高い変化率の傾向閾値は、30分毎に20mg/dLのグルコース濃度の増加する変化率である、請求項1に記載の方法。
- 糖尿病管理用システムであって、
別個の不均一な時間間隔にて被検体の流体サンプル中のグルコースレベルを測定して、ボーラス計算の入力データとしてそのような一時的なグルコースレベルを提供する一時的なグルコース計と、
別個の概して均一な時間間隔にて前記被検体のグルコースレベルを連続的に測定して、ボーラス計算に使用することができるグルコース測定データの形態でそれぞれの間隔にて前記グルコースレベルを提供する連続グルコースモニターと、
インスリンを前記被検体に送達するインスリン輸液ポンプと、
前記ポンプ、グルコース計、及び前記グルコースモニターと連通したマイクロコントローラであって、前記マイクロコントローラが前記被検体にボーラス推奨値を提供し、前記ポンプにより送達された実際のボーラスが前記ボーラス推奨値以外であるかどうか評価し、送達された前記実際のボーラスが前記ボーラス推奨値以外である場合、一定期間にわたってグルコース値の変化率の傾向を判定して、送達された実際のボーラス及びボーラス推奨値とともにユーザーに低い変化率の傾向又は高い変化率の傾向のうちの1つを報知するように構成されている、マイクロコントローラと、
を備える、システム。 - 前記低い変化率の傾向閾値は、30分毎に20mg/dLのグルコース濃度の低下率であり、前記高い変化率の傾向閾値は、30分毎に20mg/dLのグルコース濃度の増加する変化率である、請求項8に記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/098,353 | 2013-12-05 | ||
US14/098,353 US9861747B2 (en) | 2013-12-05 | 2013-12-05 | Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing |
PCT/US2014/066095 WO2015084581A1 (en) | 2013-12-05 | 2014-11-18 | Bolus dosing feedback for the management of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016540564A JP2016540564A (ja) | 2016-12-28 |
JP6549577B2 true JP6549577B2 (ja) | 2019-07-24 |
Family
ID=53270086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016534654A Active JP6549577B2 (ja) | 2013-12-05 | 2014-11-18 | 糖尿病管理用ボーラス投与フィードバック |
Country Status (11)
Country | Link |
---|---|
US (2) | US9861747B2 (ja) |
EP (1) | EP3077023B1 (ja) |
JP (1) | JP6549577B2 (ja) |
KR (1) | KR20160094391A (ja) |
CN (1) | CN105813668B (ja) |
AU (1) | AU2014357567B2 (ja) |
CA (1) | CA2932263C (ja) |
ES (1) | ES2759110T3 (ja) |
RU (1) | RU2687572C1 (ja) |
TW (2) | TWI667629B (ja) |
WO (1) | WO2015084581A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4303884A3 (en) * | 2016-01-29 | 2024-04-03 | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group | Method, system, and computer readable medium for virtualization of a continuous glucose monitoring trace |
CA3042709A1 (en) | 2016-11-03 | 2018-08-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stacked tissue encapsulation device systems with or without oxygen delivery |
CA3042866A1 (en) | 2016-11-03 | 2018-05-11 | Klearchos K. Papas | Encapsulation device systems with oxygen sensors with or without exogenous oxygen delivery |
KR102607115B1 (ko) * | 2016-11-03 | 2023-11-30 | 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 | 혈당 조절을 강화하기 위한 방법, 시스템 및 이식 장치 |
CN110267526B (zh) | 2016-11-03 | 2022-06-24 | 代表亚利桑那大学的亚利桑那董事会 | 用于在移植前后实时评估包封装置中细胞的方法和系统 |
US11497851B2 (en) | 2017-03-31 | 2022-11-15 | Lifescan Ip Holdings, Llc | Maintaining maximum dosing limits for closed loop insulin management systems |
WO2018184012A1 (en) | 2017-03-31 | 2018-10-04 | Capillary Biomedical, Inc. | Helical insertion infusion device |
US10729849B2 (en) * | 2017-04-07 | 2020-08-04 | LifeSpan IP Holdings, LLC | Insulin-on-board accounting in an artificial pancreas system |
US11147920B2 (en) * | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
AU2018261124B2 (en) | 2017-05-05 | 2021-01-28 | Ypsomed Ag | Closed loop control of physiological glucose |
EP3729446A1 (en) * | 2017-12-21 | 2020-10-28 | Eli Lilly and Company | Closed loop control of physiological glucose |
US12020797B2 (en) | 2018-06-22 | 2024-06-25 | Ypsomed Ag | Insulin and pramlintide delivery systems, methods, and devices |
TWI799725B (zh) * | 2019-08-02 | 2023-04-21 | 華廣生技股份有限公司 | 植入式微型生物感測器及其操作方法 |
US11872033B2 (en) | 2019-11-15 | 2024-01-16 | Lifescan Ip Holdings, Llc | Methods and devices for visualizing analyte measurements |
US11055119B1 (en) * | 2020-02-26 | 2021-07-06 | International Business Machines Corporation | Feedback responsive interface |
WO2021257952A1 (en) * | 2020-06-18 | 2021-12-23 | Capillary Biomedical, Inc. | Event-driven compensated insulin delivery over time |
US20220400985A1 (en) | 2021-06-18 | 2022-12-22 | Lifescan Ip Holdings, Llc | System And Method For Tracking And Presenting Glucose Monitor Data |
CN116159208B (zh) * | 2021-11-24 | 2024-03-15 | 上海微创生命科技有限公司 | 人工胰腺控制方法、可读存储介质及血糖管理系统 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
CN1859943B (zh) | 2002-10-11 | 2010-09-29 | 贝克顿·迪金森公司 | 用于控制患者体内葡萄糖的浓度的系统 |
US7778680B2 (en) | 2003-08-01 | 2010-08-17 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20070033074A1 (en) | 2005-06-03 | 2007-02-08 | Medtronic Minimed, Inc. | Therapy management system |
WO2008135098A1 (en) * | 2007-05-07 | 2008-11-13 | Unomedical A/S | Cannula and delivery device |
EP2170430A2 (en) * | 2007-06-29 | 2010-04-07 | Roche Diagnostics GmbH | Method and apparatus for determining and delivering a drug bolus |
WO2009075925A1 (en) | 2007-12-13 | 2009-06-18 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
GB2466183A (en) | 2008-12-09 | 2010-06-16 | Cambridge Entpr Ltd | Closed loop diabetes management system |
EP2427102A2 (en) | 2009-05-04 | 2012-03-14 | MediSense Technologies, LLC | System and method for monitoring blood glucose levels non-invasively |
EP2433235A2 (en) * | 2009-05-22 | 2012-03-28 | Abbott Diabetes Care, Inc. | Safety features for integrated insulin delivery system |
KR20120123444A (ko) | 2010-01-22 | 2012-11-08 | 라이프스캔, 인코포레이티드 | 분석물 검사 방법 및 시스템 |
RU2553097C2 (ru) * | 2010-02-25 | 2015-06-10 | Лайфскэн Скотлэнд Лимитед | Способ испытания аналита и система оповещения о тенденциях показаний в сторону повышения и понижения уровня глюкозы в крови |
BR112012021590A2 (pt) | 2010-02-25 | 2016-09-13 | Lifescan Scotland Ltd | detecção de capacitância em ensaio eletroquímico |
US20110313680A1 (en) | 2010-06-22 | 2011-12-22 | Doyle Iii Francis J | Health Monitoring System |
EP2628115B1 (en) | 2010-10-12 | 2015-06-03 | The Regents of The University of California | Insulin delivery device |
US8615366B2 (en) | 2010-10-15 | 2013-12-24 | Roche Diagnostics Operations, Inc. | Handheld diabetes management device with bolus calculator |
US9757510B2 (en) * | 2012-06-29 | 2017-09-12 | Animas Corporation | Method and system to handle manual boluses or meal events for closed-loop controllers |
US20140074059A1 (en) | 2012-09-12 | 2014-03-13 | Lifescan, Inc. | Method and system to indicate glycemic impacts of insulin infusion pump commands |
-
2013
- 2013-12-05 US US14/098,353 patent/US9861747B2/en active Active
-
2014
- 2014-11-18 CA CA2932263A patent/CA2932263C/en active Active
- 2014-11-18 WO PCT/US2014/066095 patent/WO2015084581A1/en active Application Filing
- 2014-11-18 AU AU2014357567A patent/AU2014357567B2/en not_active Ceased
- 2014-11-18 CN CN201480066343.6A patent/CN105813668B/zh not_active Expired - Fee Related
- 2014-11-18 JP JP2016534654A patent/JP6549577B2/ja active Active
- 2014-11-18 EP EP14867860.0A patent/EP3077023B1/en active Active
- 2014-11-18 RU RU2016126607A patent/RU2687572C1/ru not_active IP Right Cessation
- 2014-11-18 ES ES14867860T patent/ES2759110T3/es active Active
- 2014-11-18 KR KR1020167017385A patent/KR20160094391A/ko not_active Application Discontinuation
- 2014-12-03 TW TW107129096A patent/TWI667629B/zh not_active IP Right Cessation
- 2014-12-03 TW TW103141893A patent/TWI639131B/zh not_active IP Right Cessation
-
2017
- 2017-12-11 US US15/837,358 patent/US10188796B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3077023A1 (en) | 2016-10-12 |
RU2687572C1 (ru) | 2019-05-15 |
US20180104411A1 (en) | 2018-04-19 |
US20150157792A1 (en) | 2015-06-11 |
CA2932263A1 (en) | 2015-06-11 |
WO2015084581A1 (en) | 2015-06-11 |
AU2014357567A1 (en) | 2016-06-09 |
JP2016540564A (ja) | 2016-12-28 |
ES2759110T3 (es) | 2020-05-07 |
AU2014357567B2 (en) | 2019-03-28 |
TWI639131B (zh) | 2018-10-21 |
TW201843646A (zh) | 2018-12-16 |
KR20160094391A (ko) | 2016-08-09 |
US10188796B2 (en) | 2019-01-29 |
TWI667629B (zh) | 2019-08-01 |
CN105813668B (zh) | 2019-11-15 |
US9861747B2 (en) | 2018-01-09 |
EP3077023B1 (en) | 2019-09-18 |
CA2932263C (en) | 2021-11-23 |
EP3077023A4 (en) | 2017-08-16 |
CN105813668A (zh) | 2016-07-27 |
TW201535305A (zh) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6549577B2 (ja) | 糖尿病管理用ボーラス投与フィードバック | |
JP6495255B2 (ja) | 人工膵臓において閉ループコントローラを代替するセンサによりチューニング係数を制御する方法及びシステム | |
CN104394907B (zh) | 在闭环控制器中处理手动推注或膳食事件的方法和系统 | |
JP6312696B2 (ja) | 人工膵臓の閉ループコントローラ調整のための方法及びシステム | |
KR20190132684A (ko) | 인공 췌장 시스템에서의 잔존 인슐린 고려 | |
TW201503921A (zh) | 用於人工胰臟之混合式控制至目標及控制至範圍模型預測控制的方法及系統 | |
JP2019509085A (ja) | 薬物送達システムのための可視化及び解析ツール | |
US20180147348A1 (en) | Audio bolus with improved safety for use in a drug delivery system | |
RU2778069C2 (ru) | Учет остаточного количества активного инсулина в системе искусственной поджелудочной железы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170926 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190604 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190627 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6549577 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |